en · de · es · fr · pt
bpc-157-notes.peptides6608.com › Wiki › Background And Chemical Identity — Research Overview

Background And Chemical Identity — Research Overview

By Editorial Desk · published 2026-06-07 · last reviewed 2026-06-22 · Wiki

If you have been reading about BPC 157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-06-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Chemical Identity

BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.

The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.

Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.

Discovery and Research Background

BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.

Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.

Bpc-157 at a glance

PropertyValueNotes
Molar massApproximately 1419.5 g/molCalculated from the reported 15-residue sequence
Molecular formulaC62H98N16O22Based on the same sequence
AppearanceWhite to off-white powderTypical of a lyophilized preparation
Solubility classFreely soluble in waterAlso dissolves in saline solutions
Typical storage temperatureMinus 20 degrees Celsius, dryRefrigeration advised after reconstitution

Research Literature and Evidence Gaps

Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.

Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.

Related pages on this site

Storage, Handling, and Analytical Verification

Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.

Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.

Origin and Peptide Identity

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

Reference notes

[H3SO4]+[HSO4]− = 2.7 × 10−4 The corresponding equilibrium constant for water, Kw is 10−14, a factor of 1010 (10 billion) smaller. In spite of the viscosity of the acid, the effective molar conductivities of the H3SO+4 and HSO−4 ions are high due to an intramolecular proton-switch mechanism (analogous to the Grotthuss mechanism in water), making sulfuric acid a good conductor of electricity.

Molecular analysis of DNA sequences from most families of flowering plants enabled the Angiosperm Phylogeny Group to publish in 1998 a phylogeny of flowering plants, answering many of the questions about relationships among angiosperm families and species. The theoretical possibility of a practical method for the identification of plant species and commercial varieties by DNA barcoding is the subject of active current research.

==== Early career (1999–2004) ==== After having a slow start with a season high of 15 Disposals and 4 Marks, in his second season he suffered an injury and missed most of Essendons games. In McVeigh's third season however, it was clear that the game had grown on him as he stood up as an up-and-coming youngster. After playing 23 games in his third year of playing including the Grand Final against the Brisbane Lions in which Essendon lost, McVeigh had some promising stats with a consistent 11 – 18 in over half of every game he played. McVeigh also went on to play the next 3 seasons in stellar form with Essendon who reached 3 consecutive semi-finals in which McVeigh played in all.

Sources: en.wikipedia.org

Notes from published material

Theodoros "Theo" Angelopoulos (Greek: Θεόδωρος Αγγελόπουλος; 27 April 1935 – 24 January 2012) was a Greek filmmaker, screenwriter and film producer. He dominated the Greek art film industry from 1975 on, and Angelopoulos was one of the most influential and widely respected filmmakers in the world. He started making films in 1967. In the 1970s he made a series of political films about modern Greece. Angelopoulos' films, described by Martin Scorsese as those of "a masterful filmmaker", are characterized by slight movement and distance changes, long takes, and complex, carefully composed scenes. His cinematic method is often described as "sweeping" and "hypnotic." Angelopoulos has said that in his shots, “time becomes space and space becomes time.” The pauses between action or music are important to creating the total effect. In 1998 his film Eternity and a Day went on to win the Palme d'Or at the 51st edition of the Cannes Film Festival, and his films have been shown at many of the world's esteemed film festivals.

On March 14, 2016, a National Labor Relations Board (NLRB) administrative law judge concluded that Chipotle's social media policy, and more specifically its application towards an employee who posted tweets regarding wages and working conditions, violated the National Labor Relations Act (NLRA). A former Chipotle employee in Havertown, Pennsylvania, wrote a series of tweets from his personal account about hourly workers being required to work on snow days. Chipotle instructed the employee to delete the tweets. The NLRB judge determined that Chipotle's request to delete the tweets violated the NLRA even though the employee was not disciplined as a result of his tweets. In July 2021, Chipotle rolled out limited edition gold foil at participating locations to celebrate American athletes competing in Tokyo at the 2020 Summer Olympics. On October 28, 2021, Chipotle announced $1 million of burritos to be given away for free for the first 30,000 people to play the Chipotle experience on the video game Roblox. The site ended up experiencing a three-day outage, but the company clarified that it was not the fault of Chipotle. On February 16, 2023, MoneyGram Haas F1 Team announced a sponsorship deal with Chipotle. The Chipotle logo will be featured on both the nose and side of the VF-23, race-suits of drivers Kevin Magnussen and Nico Hulkenberg and team apparel.

=== Gastrointestinal system === Somatostatin is homologous with cortistatin (see somatostatin family) and suppresses the release of gastrointestinal hormones Decreases the rate of gastric emptying, and reduces smooth muscle contractions and blood flow within the intestine Inhibits adenylyl cyclase in parietal cells, thereby suppressing gastric acid secretion Suppresses the release of pancreatic hormones Somatostatin release is triggered by the beta cell peptide urocortin3 (Ucn3) to inhibit insulin release. Inhibits the release of glucagon Suppresses the exocrine secretory action of the pancreas

Sources: en.wikipedia.org

Frequently asked questions

Is BPC-157 a naturally occurring peptide?

It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.

What does the number 157 in the name indicate?

It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.

Does the molecule contain sulfur or disulfide bonds?

No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.

What is BPC-157?

It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.

Network